Analyst consensus rating
Cadrenal Therapeutics Analyst Rating: none
Direct answer
Cadrenal Therapeutics's consensus rating is none.
3 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $14.00.
Forecast evidence checked October 18, 2026.
Get free Cadrenal Therapeutics email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $1.09
- Average price target
- $14.00
- High price target
- $17.00
- Low price target
- $12.00
- Low target gap
- +1,000.9%
- Target upside
- +1,184.4%
- High target gap
- +1,459.6%
- Target range width
- 458.7%
- Consensus rating
- none
- Analysts
- 3
- Evidence date
- October 18, 2026
- Valid through
- October 25, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for Cadrenal Therapeutics?
Cadrenal Therapeutics has a verified none consensus. The same dataset has an average price target of $14.00.
How far are Cadrenal Therapeutics's low and high targets from the recorded price?
The low target implies +1,000.9%, while the high target implies +1,459.6%.
How many analysts are included in Cadrenal Therapeutics's consensus?
The verified consensus includes 3 analysts.
How is Cadrenal Therapeutics's target upside or downside calculated?
The average target of $14.00 is divided by the recorded price of $1.09, then one is subtracted to produce +1,184.4%. This does not guarantee a future return.
When was Cadrenal Therapeutics's analyst forecast verified?
The data was verified on 2026-10-18. The dataset is valid through 2026-10-25.